🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share this video of the UCSF Cardiology research and clinical efforts in cardio-oncology & cardio-immunology! #CardioOnc Myocarditis Fndn International Cardio-Oncology Society AHA Research Kiniksa Pharmaceuticals American Heart Association Nature Cardiovascular Research UCSF Health vimeo.com/1036624044

#ASCO25 💡Highlight of the Developmental Therapeutics/IO track today Catch our special session on severe IO toxicity: a real life irAE tumour board! Featuring… - Chair Sandrine Aspeslagh🇧🇪 - Med Onc #DougJohnson🇺🇸 - Cardio-Onc DrJE-Salem🇫🇷 - Neuro-Onc #JonProbasco🇺🇸 ASCO

Started Day 3 of #ASCO25 with a fantastic session on rare and severe immunotherapy-related toxicities: insightful discussions on challenges and emerging management strategies!

Excited to report this important collaboration which we hope helps us understand ICI-myocarditis better, published in #EHJ today! Along with the great DrJE-Salem! EHJ Editor-in-Chief Johann Bauersachs #CardioOnc UCSF Cardiology UCSF Helen Diller Family Comprehensive Cancer Ctr academic.oup.com/eurheartj/adva…

Here are the key risk factors: Presence of thymoma, Time of initial exposure to therapy, muscular symptoms, ECG criteria, LV dysfunction & degree of troponin elevation! Confirmed in a validation cohort through Mass General Brigham (special thanks to Osnat.Itzhaki & Anju Nohria!)

We additionally develop a risk score using these criteria which we hope helps clinicians across the globe!

Lots of new data to go through but here is one critical 1: we still have a long way to go in terms of treatment for patients. Despite some early (& flawed) data, corticosteroids do nothing (even at high doses) for patients...

This is a huge win. Many Congrats. These risk factors have helped our team identify high risk patients! More to come. #cardiooncology Pitt Cardiology UPMC Heart and Vascular Institute UPMC Hematology & Oncology Fellowship Program UPMC Hillman Cancer Center

Congratulations Javid Moslehi DrJE-Salem Aarti Asnani Han Zhu on this excellent step forward to advance our understanding of ICI myocarditis #MedTwitter #oncology #cancer #cardiotwotter

At last—our analysis predicting severe outcomes in ICI-myocarditis is out. With just ECG, LVEF, troponin, and clinical history, you can estimate risk at initial presentation. Grateful for the incredible mentorship Javid Moslehi DrJE-Salem .. true world-class investigators!

This score will help distinguish severe from mild ICI-myocarditis. Many clinical implications‼️ In my opinion, this is one of the most clinically relevant papers on this topic to date. DrJE-Salem European Society of Cardiology Journals academic.oup.com/eurheartj/adva…

Today it was presented at #ESCardioOnco2025 as one of the top 2025 papers on CardioOncology. DrJE-Salem European Society of Cardiology Journals

🚨 Top European Society of Cardiology Journals trials kicking off now in Room 2 at #ESCardioOncology2025 with Joerg Herrmann ➡️ Featuring SUCCOUR MRI and the hot-off-the-press ICI myocarditis risk score by DrJE-Salem European Society of Cardiology

The exceptionally eloquent ⁦DrJE-Salem⁩ outlining arrhythmia management in ICI myocarditis #ESCardioOnco2025 #oncology #cardiology

Very informative presentation by DrJE-Salem ⚠️ don't hurry up with antiarrhythmic therapy in ICI induced severe arrythmias and be aware of increased risk for developing of high grade conduction disorders #ESCardioOnc2025 #cardiooncology

Great science, packed rooms + so nice to meet all the collaborators and friends!!! Thanks for the perfect organization 🙏🏻#ESCardioOnco2025

Assessing the Severity and Risks of ICI-Associated Myocarditis: Key Clinical Indicators in #EHJ! academic.oup.com/eurheartj/adva… #EHJ #cardiotwitter #myocarditis #oncology @ESC_journals European Society of Cardiology

Qin et al report the first use of ruxolitinib, a non-selective JAK inhibtor, in treatment of acute fulminant myocarditis. Using single-cell profiling, Ruxolitinib was shown to attenuate JAK/STAT signaling and modulate immune profiles. ahajournals.org/doi/full/10.11…

Risk score predicts poor outcomes in ICI-myocarditis John Power Javid Moslehi DrJE-Salem: -748pts with ICI-myo -thymoma, ⬆️trop (20, 200, >2000ULN), ⬇️QRS on ECG, LVEF<50%, CVS symps, assoc w poor outcome -risk score= 81% risk, 30-day poor outcome (validated, 🇺🇸+🇫🇷cohorts)

New work by Chris Hoeger in our #CardioOnc program BIDMC CVI investigating cardiotoxicity of the commonly used Doxil/Avastin regimen rdcu.be/euyN6 Huge thanks to collaborators Sarju Ganatra, MD, FACC DrJE-Salem and BI team Nathalie Rosas, Reese Pinto, Rishi Wadhera, MD MPP, Meghan Shea